A long-term cohort study has linked TNF inhibitor therapy to an increased risk of skin cancer, adding a new data point to the risk-benefit discussion dermatologists weigh when initiating or continuing biologic treatment for conditions such as psoriasis.

The findings, reported by Dermatology Times, emerge from extended follow-up of patients receiving tumor necrosis factor inhibitors — a drug class that includes adalimumab, etanercept and infliximab — over a multi-year observation window. The cohort design captures real-world exposure patterns that randomized controlled trials, with their limited duration and stringent inclusion criteria, cannot detect.

Skin cancer risk is not a new concern in this population. Patients with moderate-to-severe psoriasis already carry an elevated baseline risk of cutaneous malignancy, driven in part by cumulative phototherapy exposure, immunosuppression and disease-related inflammatory burden. Earlier pharmacovigilance analyses and registry studies, including data from the British Association of Dermatologists Biologic Interventions Register (BADBIR), have produced mixed signals on TNF inhibitors and malignancy. This latest longitudinal analysis adds weight to the association.

The clinical implications are nuanced rather than prohibitive. TNF inhibitors remain effective, guideline-supported therapies for plaque psoriasis, psoriatic arthritis and other immune-mediated conditions, and the absolute risk of skin cancer in treated patients remains modest relative to the therapeutic benefit many patients derive. What the study does reinforce is the need for structured surveillance.

For practicing dermatologists, the practical takeaways are familiar but now better substantiated. Baseline skin examinations should precede biologic initiation, with full-body checks documenting suspicious pigmented and non-pigmented lesions. Annual — or more frequent — dermatologic surveillance is warranted for patients on continuous TNF inhibitor therapy, particularly those with additional risk factors: prior skin cancer, substantial historic PUVA or NB-UVB exposure, older age, fair skin phenotype and immunosuppression from comorbid conditions or concomitant medication.

Patient counseling also merits attention. Individuals on TNF inhibitors should receive clear guidance on sun protection, self-examination for changing lesions and prompt reporting of non-healing or bleeding growths. Where a patient has a documented history of cutaneous malignancy, clinicians may reasonably consider an alternative mechanism of action — an IL-17, IL-23 or IL-12/23 inhibitor — when the treatment decision is otherwise balanced.

The study's timing is relevant to current prescribing patterns. TNF inhibitors have lost first-line dominance in psoriasis as IL-23 inhibitors such as guselkumab and risankizumab and IL-17 agents such as secukinumab and ixekizumab have demonstrated superior PASI responses in head-to-head trials. Even so, TNF inhibitors retain an important role, especially in patients with concomitant psoriatic arthritis, inflammatory bowel disease or uveitis, where the drug class offers multi-disease coverage.

The findings also arrive amid a broader regulatory and clinical conversation about long-term safety surveillance of biologics. Post-market cohort studies of this kind represent the primary mechanism by which rare and delayed adverse signals — including malignancy — are detected after approval, underscoring their value even when effect sizes are small.

As longer follow-up accumulates on newer biologics, comparative malignancy data across drug classes will help clarify whether the observed signal is specific to TNF blockade or reflects a broader consequence of long-term immunomodulation in this patient population.